



Antibiotics and Infectious Respiratory Diseases

Guest Editors:

Dr. Francesco Di Gennaro

Respiratory Infectious Diseases
Unit, National Institute for
Infectious Diseases “L.
Spallanzani” IRCCS, 00149 Rome,
Italy

Dr. Gina Gualano

Respiratory Infectious Diseases
Unit, National Institute for
Infectious Diseases “L.
Spallanzani” IRCCS, 00149 Rome,
Italy

Dr. Fabrizio Palmieri

Director of Respiratory Infectious
Diseases Unit, National Institute
for Infectious Diseases “L.
Spallanzani” IRCCS, 00149 Rome,
Italy

Deadline for manuscript
submissions:

closed (15 March 2022)

Message from the Guest Editors

Infectious respiratory diseases (IRD) remain among the most important causes of morbidity and mortality worldwide and, in the era of the COVID-19 pandemic, they have come into major focus in the scientific world and the global health approach. They can have a viral, bacterial, parasitic, and opportunistic origin. Effective management of respiratory infectious diseases to reduce their burden and to avoid overuse of antibiotics has become a great therapeutic and public health challenge. Manuscripts covering all aspects of research relating to IRD prevention, diagnosis, management, and treatment are welcome.

In addition, manuscripts covering these areas of interest are welcome:

1. Bacterial host resistance and antimicrobial resistance;
2. HAP (hospital-acquired pneumonia), VAP (ventilator-associated pneumonia), CAP (community-acquired pneumonia);
3. Tuberculosis and nontuberculous mycobacteria (NTM);
4. Viral pneumonia and SARS CoV2 interstitial pneumonia;
5. Educational on antimicrobial resistance and antimicrobial prescription;
6. Pneumonia infection in immunocompetent and immunosuppressed patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)